Low expression of long non-coding RNA ARAP1-AS1 can inhibit lung cancer proliferation by inducing G0/G1 cell cycle organization

Background This paper examines the expression, function, and molecular mechanism of long non-coding ribonucleic acid (lncRNA) ARAP1 antisense RNA 1 (ARAP1-AS1) in lung cancer. Specifically, it aims to clarify the molecular mechanism of lncRNA ARAP1-AS1 that affects the occurrence and development of lung cancer, and provide a theoretical basis and molecular targets for targeted therapy or early diagnosis of lung cancer. Methods Fluorescence quantitative detection of lncRNA ARAP1-AS1 expression in lung cancer tissues and cell lines, and methylthiazolyldiphenyl-tetrazolium (MTT), plate cloning experiment, and flow cytometry were used to detect the effect of knockdown of lncRNA ARAP1-AS1 on cell proliferation, clone formation, and the cell cycle, respectively. Western blotting was used to detect the expression of cell cycle-related proteins as well as the effect of knockdown of lncRNA ARAP1-AS1 on lung cancer. Cell proliferation was assessed by a nude mouse subcutaneous tumor formation experiment. Results LncRNA ARAP1-AS1 is highly expressed in lung cancer tissues and cells. Knockdown of LncRNA ARAP1-AS1 can significantly inhibit the proliferation and clonal formation of lung cancer cells and induce G0/G1 cell cycle arrest. Knockdown of ARAP1-AS1 can markedly inhibit the expression of cell cycle-related protein cyclin D1, but has no significant effect on the expression of cyclin-dependent kinase (CDK)4 and CDK6. Furthermore, knockdown of ARAP1-AS1 can also notably inhibit the growth of lung cancer cells and substantially reduce the expression of Ki-67 in tumor-bearing tissues in nude mice. Conclusions LncRNA ARAP1-AS1 is highly expressed in lung cancer. Knocking down of this gene can significantly inhibit cell proliferation in vitro and in vivo, and can also cause G0/G1 cell cycle arrest by inhibiting the expression of cyclin D1.

[1]  Xiuhua Wang,et al.  Long non-coding RNA ARAP1-AS1 accelerates cell proliferation and migration in breast cancer through miR-2110/HDAC2/PLIN1 axis , 2020, Bioscience reports.

[2]  Dan-Dan Wu,et al.  Long non‐coding RNA ARAP1‐AS1 promotes tumorigenesis and metastasis through facilitating proto‐oncogene c‐Myc translation via dissociating PSF/PTB dimer in cervical cancer , 2020, Cancer medicine.

[3]  B. Cho,et al.  Dual-targeting of EGFR and Neuropilin-1 Attenuates Resistance to EGFR-targeted Antibody Therapy in KRAS-mutant Non-Small Cell Lung Cancer. , 2019, Cancer letters.

[4]  Lixin Wang,et al.  Screening of potential biomarkers and their predictive value in early stage non-small cell lung cancer: a bioinformatics analysis. , 2019, Translational lung cancer research.

[5]  Wei Huang,et al.  YY1-Induced Upregulation of Long Noncoding RNA ARAP1-AS1 Promotes Cell Migration and Invasion in Colorectal Cancer Through the Wnt/β-Catenin Signaling Pathway. , 2019, Cancer biotherapy & radiopharmaceuticals.

[6]  Song Zhu,et al.  ncRNA-Encoded Peptides or Proteins and Cancer. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Y. Allory,et al.  High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an ANRIL–ARF Bidirectional Promoter , 2019, Non-coding RNA.

[8]  Julia Chen,et al.  Osimertinib in the treatment of leptomeningeal disease in T790M-negative, epidermal growth factor receptor-mutated non-small cell lung cancer: a case report. , 2019, Chinese clinical oncology.

[9]  S. Jonna,et al.  Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. , 2019, Discovery medicine.

[10]  Zhuo-Min Jia,et al.  Long non-coding RNA ARAP1-AS1 promotes the progression of bladder cancer by regulating miR-4735-3p/NOTCH2 axis , 2018, Cancer biology & therapy.

[11]  Zhaohui Gong,et al.  Circulating lncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[12]  Hyunggee Kim,et al.  Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells , 2018, Cellular Oncology.

[13]  S. Farajnia,et al.  Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro , 2018, Journal of cellular physiology.

[14]  J. Tu,et al.  LncRNA-DANCR: A valuable cancer related long non-coding RNA for human cancers. , 2018, Pathology, research and practice.

[15]  Wei Liu,et al.  Cav-1 promote lung cancer cell proliferation and invasion through lncRNA HOTAIR. , 2018, Gene.

[16]  L. Müllauer,et al.  Molecular pathology of lung cancer: current status and perspectives , 2017, Current opinion in oncology.

[17]  Thomas John,et al.  Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Y. Mo,et al.  LncRNA-mediated regulation of cell signaling in cancer , 2017, Oncogene.

[19]  Wen-Xing Li,et al.  Comprehensive Analysis of lncRNA and mRNA Expression Profiles in Lung Cancer. , 2017, Clinical laboratory.

[20]  S. Dalton Linking the Cell Cycle to Cell Fate Decisions. , 2015, Trends in cell biology.

[21]  Rosario Distefano,et al.  ncRNA Editing: Functional Characterization and Computational Resources. , 2019, Methods in molecular biology.

[22]  I. Wistuba,et al.  Diagnosis and Molecular Classification of Lung Cancer. , 2016, Cancer treatment and research.